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ABSTRACT 
 
Osterix is a transcription factor that is essential for osteoblast differentiation and 
periostin is a matricellular protein that, in the jaw bones, is expressed in the periosteum 
and periodontal ligament (PDL).  It has been hypothesized that the co-expression of 
osterix and periostin supports a histogenesis of PDL origin. The purpose of this study 
was to investigate the expression patterns of periostin and osterix in some jawbone 
lesions and correlate the results with current concepts regarding the cell of origin of 
these bone diseases.  We also wanted to test whether or not the co-expression of 
periostin and osterix are indeed PDL- specific.  We investigated the expression patterns 
of periostin and osterix, using immunohistochemistry, in cases of cemento-osseous 
dysplasia (COD), ossifying fibroma of the jawbones (OFJ), osteoblastoma of the 
jawbones (OBJ), odontogenic myxoma (OM), osteosarcoma of the jawbones (OSJ), 
osteosarcoma of the long bones (OSL) and osteoblastoma of the long bones (OBL).  All 
bone lesions (n=57) selected for this study stained positive for periostin.  For osterix 
expression, COD, OSJ, OBL, and most cases of OFJ, OM and OBJ showed positive 
results. OSL, except for the anaplastic/fibroblastic histological variant, also showed 
osterix expression. As there is no PDL in the long bones, these results demonstrated that 
the co-expression of these two proteins was not PDL-specific.  The co-expression of 
osterix and periostin in OM lesional cells suggest a potential differentiation for 
osteogenesis or PDL origin, despite no calcified material is found in this neoplasm.  We 
also report a novel finding that osterix-positive cells and periostin expression were found 
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in the lamina propria, and osterix-positive cells were also found in squamous epithelium 
of normal gingival mucosa.  
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1. INTRODUCTION 
 
Osterix is a transcription factor that is essential for osteoblast differentiation (1).  
Periostin is a matricellular protein that, in the jaw bones, is expressed in the periosteum 
and periodontal ligament (PDL)(2).  Co-expression of osterix and periostin has been 
found in cementoblasts and in PDL progenitor cells, thereby suggesting a pattern 
supporting PDL origin (3). The purpose of this project is to investigate the expression 
patterns of periostin and osterix in some odontogenic and non-odontogenic lesions, and 
correlate the results with current concepts regarding the histogenesis of these bone 
diseases.  The specific aim is to investigate the expression patterns of osterix and 
periostin, using immunohistochemistry, in cases of cemento-osseous dysplasia (COD), 
ossifying fibroma of the jawbones (OFJ), osteoblastoma of the jawbones (OBJ), 
odontogenic myxoma (OM), osteosarcoma of the jawbones (OSJ), and compare to the 
results osteosarcoma of the long bones (OSL) and osteoblastoma of the long bones 
(OBL).   
According to the current concepts that odontogenic myxomas are derived from 
odontogenic ectomesenchyme, that COD and OFJ originate from the periodontal 
ligament, and OBJ, OBL, OSJ and OSL are derived from osteoblasts, we hypothesize 
that the expression patterns will be as seen in Table 1:  
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Table 1: Hypothesis of Periostin and Osterix Expression Patterns. 
 COD OFJ OBJ OBL OSJ OSL OM 
Periostin + + - - - - - 
Osterix + + + + + + - 
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2. BACKGROUND AND SIGNIFICANCE 
 
While bone diseases theoretically can affect any bone in the skeletal system, 
some bone diseases do appear to be limited to the jaw bones.  For decades, pathologists 
speculated that the lesional cells in those bone diseases unique to the jaw bones most 
likely originated from cells involved in odontogenesis.  No evidence beyond histological 
features and the unique anatomic location is currently available to support their 
speculation.  The recent findings of osterix and periostin expression during 
odontogenesis demonstrate that the co-expression of these two proteins is a feature 
suggesting PDL origin (3).  These findings provided a basis to test the speculation 
regarding the cell origin of those odontogenic diseases.  
Benign fibro-osseous lesions (BFOL) are a diverse group of processes that are 
characterized by replacement of normal bone by fibrous tissue containing a newly 
formed mineralized product (4).  Cemento-osseous dysplasia and ossifying fibroma are 
two of the most common BFOL that occur in the jaw bones.  While cemento-osseous 
dysplasia is unique to the jaws, ossifying fibroma can also occur in bones from other 
regions (5, 6).        
Cemento-osseous dysplasia can be divided into periapical cemento-osseous 
dysplasia (PCOD), focal cemento-osseous dysplasia (FCOD) and florid cemento-osseous 
dysplasia (FLCOD).  PCOD and FCOD represent the most common fibro-osseous 
lesions of the jaws (4, 6-8).  All of the cemento-osseous dysplasias occur in tooth-
bearing areas. PCOD predominantly involves the periapical region of the anterior 
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mandible while FCOD exhibits a single site of involvement not in the anterior mandible.  
FLCOD denotes the most extensive form with multifocal involvement of the jaws not 
limited to the anterior mandible.  PCOD and FLCOD are most commonly found in 
middle-aged black women, although it may also occur in Caucasians and Asians (9).  
FCOD typically presents as an asymptomatic, focal, mixed radiolucent/radiopaque lesion 
with ill-defined borders in the tooth-bearing areas. It was found to occur with greater 
frequency in women (88%) and in the posterior mandible (77%)(8).   Histologic features 
include a cellular fibrous connective tissue stroma punctuated by irregular osseous 
and/or cementum-like calcifications. Because cemento-osseous dysplasia is limited to 
the jaws and arises in close proximity to the periodontal ligament, most investigators 
believed that these lesions are of PDL origin (9).    
Ossifying fibroma is a true neoplasm with a significant growth potential.  The 
most common form of ossifying fibroma occurs in the maxilla and mandible and is 
typically painless, presenting with expansion of the buccal and lingual corteces where it 
may expand the inferior aspect of the mandible (10). The radiographic features for OFJ 
are variable, depending on the amount of calcifications.  Usually, they are well 
circumscribed and often associated with the roots of teeth. Histologically, OFJ is 
characterized by a variably spindled fibroblastic stroma with varying amounts of 
mineralized material (bone and/or cementum-like calcifications)(9). In some cases, 
ossifying fibroma can resemble cemento-osseous dysplasia both radiographically and 
histopathologically.  
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As the mineralized material in ossifying fibroma includes bony trabeculae and 
cementum-like material, it has been suggested that the origin of this neoplasm is 
odontogenic and of PDL origin.  However, neoplasms microscopically identical to an 
ossifying fibroma have also been reported in long bone and other craniofacial bones such 
as the orbital, frontal, ethmoid, sphenoid, and temporal bones, leaving these prior 
theories of origin open to question (6).  Therefore, the cell of origin of ossifying fibroma 
is still unclear. Osteoblastoma is considered a fibro-osseous lesion from osteoblastic 
origin that is found most often in vertebrae, calvarium, long bones and occasionally in 
the jaw bones (4).        
 Odontogenic myxomas (OM) are benign neoplasms that are believed to arise 
from odontogenic ectomesenchyme, although this is still a topic of debate among 
pathologists (Neville)(4). Other odontogenic tissues that arise from odontogenic 
mesenchyme are the dental papilla, follicle, and periodontal ligament.  The evidence for 
odontogenic origin arises from its almost exclusive location in the tooth bearing areas of 
the jaws, its occasional association with missing or unerupted teeth, and the presence of 
odontogenic epithelium(11). According to the World Health Organization (WHO), OM 
is classified as benign tumor of ectomesenchymal origin with or without odontogenic 
epithelium (12). The odontogenic nature of the myxomas has been challenged by some 
authors because of its appearance and while consistent with odontogenic 
ectomesenchyme, it could also represent a more primitive fibroblastic or undifferentiated 
cell origin (13). 
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Osteosarcoma of the jaws is a rare entity that accounts for 6-8% of all 
osteosarcomas (4).  The vast majority of head and neck osteosarcomas arise in either the 
mandible or maxilla (15).  Extragnathic osteosarcoma occurs predominantly in the 
metaphysis of the long bones of adolescents and young adults.  It is a malignancy of 
mesenchymal cells that have the ability to produce osteoid or immature bone.  The 
majority of osteosarcomas demonstrate intramedullary origin.  The typical radiographic 
appearances of osteosarcoma are a destructive mass and immature cloudlike bone 
formation in the metaphyses of long bones (16).  Osetosarcomas of the jaws demonstrate 
a variety of histologic features but the essential microscopic criterion is the direct 
production of osteoid by malignant mesenchymal cells.  
Osterix, a recently identified zinc finger–containing transcription factor, is 
expressed in the osteoblasts of all endochondral and membranous bones and is required 
for osteoblast differentiation and bone formation (1, 17-28).  Osterix is required to 
maintain osteoblast function following adult bone maintenance (29).  In humans, two 
isoforms have been identified and named  Sp7-a and -b isoforms, sharing 95% sequence 
homology with murine Osx (30, 31).  In osterix-null mutant mice, endochondral and 
intramembranous bone formation is arrested, evidence that osteoblast differentiation is 
prevented (32, 33).  Osterix is also important for differentiation into both acellular and 
cellular cementoblasts (34) as well as in the odontoblasts and PDL cells (3, 35-37).  
However, its role in bone tumor development is not fully understood.  As a transcription 
factor, osterix exhibits nuclear staining in osteogenic lineage cells, in 
immunohistochemistry.  
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Periostin is a matricellular glutamate-containing protein that was originally 
isolated as an osteoblast-specific factor that functions as a cell adhesion molecule for 
preosteoblasts and is thought to be involved in osteoblast recruitment, attachment, and 
spreading (2).  Periostin protein is later found to be expressed in a wide variety of 
normal adult tissues and fetal tissues, such as periosteum (adult and fetal,) skin, PDL, 
jawbones near developing teeth, placenta, adrenal glands, lung, thyroid, stomach, colon, 
vagina, ovary, testis, prostate, heart and breast (38-49).  Periostin has also been found to 
be involved in the progression and invasion of certain cancers (50-54), and may be a 
marker for prediction of malignant behavior in head and neck squamous cell carcinoma 
and nasopharyngeal carcinoma (64-66).  It is considered a potent angiogenic factor and a 
marker of tumour progression in many types of human cancer (67-69).  The protein was 
renamed "periostin" because of its expression in the periosteum and PDL, indicating a 
potential role in bone and maintenance of tooth structure (2, 55-57).  Occlusal force is 
thought to be important in the homeostasis of the PDL.  These forces might have a role 
in periostin expression in the PDL and the changes in its expression level during 
hypofunction may be considered a form of adaptation to environmental changes (58-60).  
Periostin plays an important role in the determination of bone mass and microstructure in 
response to loading (61).  Periostin is a novel marker for intramembranous ossification, 
and has been suggested to be a good candidate as a diagnostic tool and/or a therapeutic 
target in fibrous dysplasia (62).  Periostin expression should be found in the extracellular 
matrix and in the cytoplasm of the cell when using immunohistochemistry. 
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The purpose of this project is to investigate the expression patterns of periostin 
and osterix in some odontogenic and non-odontogenic lesions, and correlate the results 
with current concepts regarding the cell of origin of these bone diseases. While osterix is 
expressed in both osteoblasts and cementoblasts in the jawbones, the co-expression with 
periostin (secreted products) would indicate that the cell type is PDL progenitor cells, 
not osteoblasts.  The specific aim is to investigate the expression patterns of osterix and 
periostin, using immunohistochemistry, in cases of cemento-osseous dysplasia (COD), 
odontogenic myxoma (OM), ossifying fibroma of the jawbones (OFJ), osteoblastoma of 
the jawbones (OBJ), osteoblastoma of the longbones (OBL), osteosarcoma of the 
jawbones (OSJ) and osteosarcoma of the long bones (OSL).  The lesional cells of COD 
and OFJ have been speculated to be of PDL origin, and the neoplastic cells in OFL, OSJ 
and OSL are believed to show osteoblast differentiation not derived from PDL. 
Odontogenic myxomas are believed to arise from odontogenic ectomesenchyme and 
have no osteoid product.  The proposal will test the current concepts of histogenesis 
regarding these bone diseases.  The results of this study may provide evidence 
supporting the speculation of the cell origin in odontogenic and non-odontogenic 
diseases in the jawbone, and/or provide new diagnostic biomarkers differentiating COD 
and OFJ from other bone diseases. 
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3. MATERIALS 
 
Formalin-fixed, paraffin embedded human archival specimens and related 
clinical information (gender, age, duration, location of the lesion, clinical presentation 
and radiograph, if available) will be retrieved from the database of the Department of 
Diagnostic Sciences, TAMU-Baylor College of Dentistry.  Ten cases of each of the 
following diagnosis will be selected: 
a) COD: Cemento-osseous dysplasia (periapical, focal, or florid) 
b) OM: Odontogenic myxoma 
c) OFJ: Ossifying fibroma from the jawbone 
d) OSJ: Osteosaroma, osteoblastic or chondroblastic types, from the 
jawbone 
e) OBJ: Osteoblastoma from the jawbone 
For comparison purposes, ten cases (formalin-fixed, paraffin embedded human 
archival specimens and related clinical information, as described above) of each of the 
following diagnosis also will be selected from the database of the Department of 
Pathology, Baylor University Medical Center (BUMC): 
a) OBL: Osteoblastoma of the longbone, without periosteum involvement 
b) OSL: Osteosarcoma of the long bone, without periosteum involvement 
An established immunohistochemistry protocol, for the two antibodies, will be 
followed. The following is a list of supplies utilized in the protocol: Xylene (StatLab, 
Lewisville, Texas), Reagent alcohol (StatLab, Lewisville, Texas),30% Hydrogen 
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Peroxidase (Fisher Scientific, #704922), phosphate buffered solution (PBS) (Sigma), 
Bovine Serum Albumin (Sigma, A3059), Goat Serum (Vector, S-1000), Rabbit anti-
OSX (Abcam, ab22552), Rabbit anti-periostin (Innovative Research, IR100000)), 
Biotinylated  anti-rabbit IgG (Vector, #BA-1000), ABC Peroxidase Kit (Vector PK-
4000),  DAB (Sigma, D5637-25G), Trisodium Chloride (Fischer Scientific, EC 201-064-
4), Sodium Hydroxide, Citric acid buffer, Sodium citrate buffer, Tween-20 (Fischer 
Scientific, EC 500-018-3), alarm timer (VWR, Suwanee, GA), latex gloves (VWR, 
Suwanee, GA), Sterile serolocial pipets (VWR, Suwanee, GA), Accu-mount60 (Baxter, 
McGaw Park, IL) 
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4. METHODS 
 
Tissue sections (4 micrometers in thickness) will be obtained from the selected cases 
as described above.  The slides will be de-paraffinized with xylene and rehydrated with 
decreasing concentrations of reagent alcohol followed by phosphate buffered saline 
(PBS).  Antigen retrieval will be done by steaming the slides in 10mM sodium citrate 
buffer (pH =6.0) for 10 minutes.  Endogenous peroxidase activity will be inhibited with 
3% hydrogen peroxide buffer (Fischer Scientific, #704922).  The slides will then be  
rinsed with PBS, blocked 3% bovine serum albumin (BSA) and 20% goat serum, 
followed by incubating with primary antibodies, diluted in 20% goat serum in PBS 
overnight at 4 °C.  The primary antibodies that will be used include OSX rabbit anti-
human (Abcam, 1:400) and Periostin rabbit anti-human (Innovative Research, 1:1000) 
antibodies.  The slides will then be washed with PBS and incubated with biotinlylated 
anti-rabbit IgG (1:200, Vector, #BA-1000) for one hour, at room temperature..  After 
washing with PBS, antibody detection will be accomplished using ABC peroxidase kit 
(Vector, PK-4000), following the manufacturers’ instructions. The slides will then be 
incubated with the substrate solution containing diaminobenzidine tetrahydrochloride 
(DAB, Sigma, D5637-25G) in50 mM trisodium chloride (Fischer Scientific, EC 201-
018-3), pH = 7.4.  The slides will be counterstained with hematoxylin, dehydrated with 
ascending concentrations of reagent alcohol followed by three washes of xylene, and 
then mounted with coverslips with Accu-mount (Baxter, McGaw Park, IL).  Sections 
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incubated with BSA without the primary antibody will be used as the negative control. 
Sections consisting of periodontal ligament tissue will be used as the positive control. 
The expression of osterix and periostin in the specimens will be described based on 
the observation under the light microscope.  Representative images will be 
photographed. Based on the literature, osterix expression should be found in the nucleus, 
and periostin expression should be found in the cytoplasm of the cells and in the 
extracellular matrix. 
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5. RESULTS 
 
The result of periostin and osterix IHC staining is summarized in Table 2 (Page 
15).  Of the 45 odontogenic bone lesions and 12 non-odontogenic bone lesions (n=57) 
selected for this study, all stained positive for periostin.  However, the staining pattern 
varied slightly among the various cases.  For those lesions with any osteoid or cartilage 
formation, strong positive staining was found in the matrix adjacent to the lesional cells 
and less intensity in the connective tissue stroma away from the lesional cells (Figure 
1B-10B).  In the areas of the lesion where there is minimal matrix formation, the staining 
was more uniform in its intensity (Figure 11B).  It was also apparent that periostin 
stained the wall of blood vessels (Figure 5B).  For odontogenic myxoma, our only lesion 
without matrix formation, the majority of lesional tissue stained for periostin, with focal 
areas that did not stain (Figure 6B).  The intensity of the staining was uniform for all 
cases of OM.  
For osterix expression, most of the cases selected for this study showed positive 
results, although some cases of OFJ, myxoma, OBJ, and OSL were negative (See Table 
1).  All cases of COD expressed osterix, with 70% of the cases showing positive nuclear 
staining in more than 50% of the lesional cells, and 30% of the cases expressing focal 
positivity (positive staining in <50% of the lesional cells).  The staining was consistently 
found in the cells adjacent to the calcified material and occasionally found in the cells 
within the matrix (Figure 1C).  
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For COF, all but one of the eleven cases were positive (91%) for osterix 
expression.  Positive staining was found in more than 50% of the lesional cells in nine 
out of 11 cases of COF (82%)(Figure 2C), while one case showed positive staining in 
less than 50% of the lesional cells.  Seventy-five percent of osteoblastoma of the 
jawbone (n=4) were positive for osterix with one case showing negative result for osterix 
(Figure 4C).  One of the three positive cases had nuclear staining in more than 50% of 
the lesional cells (Figure 3C) and the other two cases were focally positive (positive 
staining in <50% of the lesional cells).  Both longbone cases of osteoblastoma were 
positive for osterix (100%) and had nuclear staining in >50% of the lesional cells (Figure 
5C).  
For OM, 8 of the 10 cases were positive for osterix with 50% of the cases 
showing positive nuclear staining in more than 50% of the lesional cells, and 30% of the 
cases expressing focal positivity (positive staining in <50% of the lesional cells).  With 
no osteoid product in the lesional tissue, all nuclear staining was found in the stellate, 
spindle and round cells within the myxoid stroma (Figure 6C).  Two cases did not show 
any nuclear staining for osterix (Figure 7C).  
Cases of osteosarcoma can be sub-classified based on their histological features.  
A majority of the cases used in our study showed conventional features (osteoblastic 
osteosarcoma; OSJ Figure 8A, OSL Figure 10A).  One case of OSL had a background 
predominantly composed of multinucleated giant cells (giant cell rich osteosarcoma, 
Figure 13A) and five cases of OSL were composed primarily of spindle cells with or 
without anaplastic features (fibroblastic osteosarcoma; Figure 11A and anaplastic 
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osteosarcoma; Figure 12A).  The amount of osteoid found in these five cases was 
minimal.  Of the 10 osteosarcoma of jawbone cases we retrieved from the database of 
BUMC and BCD, there were 6 cases of osteoblastic osteosarcoma and 4 cases of 
chondroblastic osteosarcoma.  All cases of osteosarcoma of the jawbones were positive 
for osterix with 70% of the cases showing positive nuclear staining in >50% of the 
lesional cells, and 30% of the cases expressing focal positivity (positive staining in 
<50% of the lesional cells).   
All osteoblastic and giant cell rich osteosarcomas of the longbone were positive 
for osterix.  Three of the five positive cases (2 osteoblastic, 1 giant cell rich) had positive 
nuclear staining in >50% of the leisonal cells.  No nuclear staining was seen in the giant 
cells present in the giant cell rich osteosarcoma.  The other two cases of the osteoblastic 
variant were focally positive (<50%).  The five cases of anaplastic or fibroblastic 
osteosarcoma were negative for osterix.  Representative photomicrographs of each 
histological variant of osteosarcoma of the long bone are shown in Figures 10 through 
13.  
One interesting and unexpected finding was noted in a case of osteosarcoma of 
the jawbone where the biopsy material included osteosarcoma and the overlying oral 
mucosal tissue (Figure 14A).  Positive staining for periostin and osterix, respectively, 
were found in focal areas in the neoplasm (Figure 14B and C).  However, positive 
staining for periostin was also seen in the fibrous connective tissue and basement 
membrane in the superficial lamina propria overlying the neoplasm (Figure 14D and E).  
Positive nuclear and cytoplasmic staining for osterix was also found in some cells in the 
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superficial lamina propria and surface squamous epithelium overlying the neoplasm 
(Figure 14F and G).  As periostin expression has not been reported in superficial lamina 
propria and osterix expression has not been reported in oral mucosal soft tissue, we 
further investigated their expression in a case of fibroma from the buccal mucosa (Figure 
15A) and two cases of fibroma from the gingiva (Figure 16A).  Neither periostin (Figure 
15B) nor osterix (Figure 15C) was found to be expressed in the normal oral epithelium 
or laminar propria in the fibroma from buccal mucosa.  Periostin (Figure 16B) and 
osterix (Figure 16C) was expressed in the normal mucosal epithelium and lamina propria 
in the gingival fibromas. 
 
Table 2: Summary of IHC Results for Periostin and Osterix Expression. 
        
Diagnosis 
  
n 
  
Osterix 
  
   Periostin   
   
      Cemento-osseous dysplasia 
 
10 + (100%)  + (100%) 
  Ossifying fibroma of jawbone 
 
11 + (100%)   + (91%) 
  Osteoblastoma of jawbone 
 
4 + (100%)   + (75%) 
  Osteoblastoma of longbone 
 
2 + (100%)  + (100%) 
  Odontogenic myxoma 
 
10 + (100%)   + (80%) 
  Osteosarcoma of jawbone 
      
 
Osteoblastic 
 
6 + (100%)  + (100%) 
  
 
Chondroblastic 
 
4 + (100%)  + (100%) 
  Osteosarcoma of longbone 
      
 
Osteoblastic 
 
4 + (100%)  + (100%) 
  
 
Anaplastic/fibroblastic 
 
5 + (100%)   - (0%) 
  
 
Giant cell rich 
 
1 + (100%)  + (100%) 
  
        Total   57 57 49   
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6. DISCUSSION 
 
The purpose of this project was to investigate the expression of periostin and 
osterix in some odontogenic and non-odontogenic lesions, and correlate the results with 
current concepts regarding the cell of origin of these bone diseases.  We investigated the 
expression patterns of osterix and periostin, using immunohistochemistry, in cases of 
COD, OFJ, OM, OBJ, OBL, OSJ, and OSL.  As the co-expression of periostin and 
osterix has been suggested to be a pattern for periodontal ligament (PDL) cell origin (3), 
we used it as evidence to determine whether the bone diseases selected in this study were 
of PDL origin or not, and used long bone lesions as a negative control to test whether 
this determining criterion was true.   
Our results showed that all cases of osteoblastoma of long bone and all cases of 
osteosarcoma of long bone, except the anaplastic/fibroblastic variants, co-expressed 
periostin and osterix.  As there is no PDL in the long bones, these results did not support 
using the co-expression of these two biomarkers for indicating PDL origin.  However, 
this finding also could be due to the possible periosteum involvement in the biopsies of 
these longbone lesions. The bony biopsies are always fragmented and there is no way to 
determine the location of the biopsy specimen relative to periosteum.  It was also not 
clear in the clinical histories of these cases whether or not these long bone biopsies were 
close to the periosteum.  Therefore, we could only conclude that co-expression of 
periostin and osterix cannot be used to determine the cell of origin of odontogenic and 
non-odontogenic bone lesions in human biopsy specimens.     
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No previous study has investigated the IHC expression pattern of periostin and 
osterix in the bone diseases selected in our study. We found that all of our cases stained 
positive for periostin.  There is a tendency of an increased intensity for periostin at the 
periphery of osteoid or cartilaginous matrix, especially in cases of COD and OFJ.  This 
finding might be explained by considering that normal periosteum, where periostin 
expression is found, is located at the periphery of bone and that the neoplastic cells at the 
periphery of osteoid or calcifications in those bone lesions might be activated to express 
periostin.  Our finding that periostin was expressed in all cases of our benign fibro-
osseous lesions (COD, OFJ, and OBJ) also appears to be consistent with the finding 
from a previously published study that periostin was also expressed in fibrous dysplasia 
(62), another disease in the benign fibro-osseous lesion category.   
Osterix was expressed in the majority of the cases included in our study.  Osterix 
was expressed in 75% of OBJ. The two cases of OBL in this study were both positive for 
periostin and osterix.  However, a weakness of this result is the small number of cases.  
We initially wanted to obtain 10 cases to the results but due to the rare nature of this 
lesion at our institution, we were unable to obtain this number.  Therefore, further 
investigation will be needed to confirm this preliminary result. 
We sub-classified OSL cases into different histological variants, as we found that 
there was a difference in periostin and osterix expression among different histological 
variants. The cases in the anaplastic/fibroblastic variant consistently showed negative 
result for osterix, despite a positive result for periostin.  We speculate that this may be 
related to the dedifferentiation of the neoplastic cells. The anaplastic feature indicates a 
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wide range of aberrant gene expression in these neoplastic cells and the aberrant 
pathway appears to include early stage of osteogenesis and the transcription factor, 
osterix.           
 With regards to OM, our results did not support our hypothesis, that no periostin 
or osterix expression would be seen. Interestingly, even in the absence of osteoid, the 
neoplastic cells in OM still express osterix and periostin.  The expression of osterix 
provided evidence for the potential for osteogenesis although we still cannot determine 
whether or not the lesional cells may be of PDL origin.  Further investigation of SOST 
expression in OM may be helpful in confirming the osteogenic but not PDL origin of 
this neoplasm.  In our OM cases, all but 2 cases showed positive staining for osterix and 
we could not find any histological differences in these two cases from the other cases 
that stained positive for osterix.          
 An interesting finding was noted in one case of OSJ, where oral mucosa was 
included in the biopsy specimen, periostin was found in the lamina propria and osterix 
was found in the squamous epithelium overlying the neoplasm (Figure 14).  Both 
periostin and osterix have not been reported to be expressed in normal oral mucosal 
fibrous connective tissue or surface epithelium.  We didn’t know if they would be 
expressed in normal oral mucosal soft tissue. Therefore, we did additional IHC studies 
for periostin and osterix in normal mucosal soft tissue involving buccal mucosa and 
gingiva.  We used fibroma cases for this purpose.  Fibroma is a reactive oral lesion 
characterized by a thickening of fibrous connective tissue that forms a lump.  The 
overlying epithelium is normal and the thickening of the connective tissue is believed to 
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be reactive change to local irritants.  Both the epithelium and the fibrous connective 
tissue are histologically the same as normal oral mucosa.      
 As we demonstrated that normal gingival mucosa without osteosarcoma 
expressed both periostin and osterix, we report this novel finding.  Further investigation 
to characterize the periostin-positive cells and osterix-positive cells in normal oral 
mucosa is needed.  
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7. CONCLUSION 
 
 
We conclude that: 
1) The co-expression of periostin and osterix is not restricted to PDL, and we 
cannot use this co-expression to test whether the lesional cells are of 
odontogenic or non-odontogenic origin in human biopsy specimens. 
2) Both periostin and osterix are expressed in COD, OFJ, OM, osteoblastoma 
and osteosarcoma except the anaplastic or fibroblastic variant of 
osteosarcoma. 
3) The expression of osterix in OM indicates a differentiation toward an 
osteogenic pathway, although the possibility of PDL origin cannot be totally 
excluded. 
4) Osterix-positive cells and periostin expression are found in the lamina propria 
and squamous epithelium of normal oral mucosa. Further characterization of 
these osterix-positive cells is needed to determine their nature. 
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APPENDIX 
 
 
Figure 1.  Representative histology and IHC result for COD. A: Histologically, COD is 
characterized by osteoid or cementum-like calcifications in a fibrous stroma (H&E stain, 
original magnification at X100). B: Periostin expression was seen throughout the 
connective tissue stroma with a slight increase in intensity in the fibrous stroma adjacent 
to the osteoid (original magnification X100). C:  Osterix expression was seen in the 
nuclei of the lesional cells in the fibrous stroma as well as the cells within the 
calcifications (original magnification X100). 
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Figure 2.  Representative histology and IHC result for OFJ. A: Histologically, OFJ 
consists of fibrous tissue that exhibits varying degrees of cellularity and contains 
mineralized material (H&E stain, original magnification X100).  B: Periostin expression 
was seen throughout the connective tissue stroma with a slight increase in intensity in 
the fibrous stroma adjacent to the osteoid (original magnification X100).  Osterix 
expression was seen in the nuclei of the cells adjacent to the osteoid as well as in the 
cells within the calcifications (original magnification X100).    
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Figure 3.  Representative histology and IHC result for OBJ. A: Histologically, OBJ is 
characterized by a mineralized material, with prominent reversal lines, lined by plump 
osteoblasts (H&E stain, original magnification X100).  B: Periostin expression was seen 
throughout the connective tissue stroma with a slight increase in intensity in the fibrous 
stroma adjacent to the osteoid (original magnification X100). C:  Osterix expression was 
seen in the nuclei of the cells adjacent to the osteoid as well as within the osteoid 
(original magnification X100). 
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Figure 4 . A: Histological features of OBJ that showed no osterix expression (H&E 
stain, original magnification X100). B: Periostin expression was still seen throughout the 
connective tissue stroma with a slight increase in intensity in the fibrous stroma adjacent 
to the osteoid (original magnification X100). C: No osterix expression was found 
(original magnification X100). 
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Figure 5.  Representative histology and IHC result for OBL.  A: Histologically, OBJ is 
characterized by a mineralized material, with prominent reversal lines, lined by 
numerous osteoblasts (H&E stain, original magnification X100).  B: Periostin expression 
was seen throughout the connective tissue stroma with a slight increase in intensity in 
the fibrous stroma adjacent to the osteoid and in the blood vessel walls (original 
magnification X100). C: Osterix expression was seen in the nuclei of the cells mostly 
adjacent to the osteoid and some within the osteoid (original magnification X100). 
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Figure 6.  Representative histology and IHC result for OM. A: Histologically, OM is 
characterized by haphazardly arranged stellate, spindle shaped, and round cells in an 
abundant, loose myxoid stroma (H&E stain, original magnification X100). B: Periostin 
expression was seen throughout the connective tissue stroma (original magnification 
X100). C: Osterix expression was seen in the nuclei of the lesional cells (original 
magnification X100). 
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Figure 7.  Representative OM case that showed no osterix expression. A: Histological 
features were similar to those seen in other myxoma cases (H&E stain, original 
magnification X100). B: Periostin expression was seen throughout the connective tissue 
stroma (original magnification X100). C: No osterix expression was found (original 
magnification X100). 
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Figure 8.  Representative histology and IHC result for the osteoblastic osteosarcoma of 
jawbone (OSJ).  A: Histologically, the osteoblastic variant is characterized by the direct 
production of osteoid by malignant mesenchymal cells ( H&E stain, original 
magnification X100). B: Periostin expression was seen throughout the connective tissue 
stroma (original magnification X100).  C:  Osterix expression was seen in the nuclei of 
the cells adjacent to the osteoid as well as within the osteoid (original magnification 
X100). 
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Figure 9.  Representative histology and IHC result for chondroblastic osteosarcoma of 
jawbone (OSJ). A:   Histologically, the chondroblastic variant is characterized by the 
direct production of cartilage, as well as osteoid, by malignant mesenchymal cells (H&E 
stain, original magnification X100).  B: Periostin expression was seen throughout the 
connective tissue stroma (original magnification X100). C:  Osterix expression was seen 
in the nuclei of the cells adjacent to the osteoid as well as within the osteoid but not in 
the immature cartilage (original magnification X100). 
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Figure 10.  Representative histology and IHC result for osteoblastic osteosarcoma of 
longbone (OSL). A: Histologically, the osteoblastic variant is characterized by the direct 
production of osteoid by malignant mesenchymal cells (H&E stain, original 
magnification X100).  B: Periostin expression was seen throughout the connective tissue 
stroma (original magnification X100). C:  Osterix expression was seen in the nuclei of 
the cells adjacent to the osteoid as well as within the osteoid (original magnification 
X100). 
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Figure 11. Representative histology and IHC result for fibroblastic osteosarcoma of 
longbone (OSL). A: Histologically, the fibroblastic variant is characterized by malignant 
mesenchymal spindle cells producing osteoid (H&E stain, original magnification X100).  
B: Periostin expression was seen throughout the connective tissue stroma (original 
magnification X100). No osterix expression was seen (original magnification X200). 
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Figure 12.  Representative histology and IHC result for the anaplastic osteosarcoma of 
longbone (OSL).  A: Histologically, the anaplastic variant is characterized by the 
minimal production of osteoid by malignant mesenchymal cells that show wide 
variations in cell size and shape (H&E stain, original magnification X100).  B: Periostin 
expression was seen throughout the connective tissue stroma, with variable intensity 
(original magnification X100).  C: No osterix expression was found (original 
magnification X100). 
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Figure 13. Representative histology and IHC result for the giant cell rich osteosarcoma 
of longbone (OSL). A: Histologically, the giant cell-rich variant is characterized by the 
production of osteoid by malignant mesenchymal cells with numerous giant cells 
throughout the  lesion (H&E stain, original magnification X100).  B: Periostin 
expression was seen throughout the connective tissue stroma (original magnification 
X100). C:  Osterix expression was seen in the nuclei of the cells adjacent to the osteoid 
as well as within the osteoid (original magnification X100). 
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Figure 14.  The expression of periostin and osterix in the epithelium and lamina propria 
overlying an osteosarcoma of the jawbone A: The histology of this case showed that the 
osteosarcoma had eroded the cortical bone and was approaching the oral mucosal 
surface (H&E stain, original magnification X50).  B: Periostin expression was seen in 
focal areas in the neoplasm (original magnification X100). C: Nuclear staining for 
osterix was found in the neoplastic cells in some areas (original magnification X100). D 
and E: Periostin expression was also found in the basement membrane area and 
superficial lamina propria overlying the neoplasm  (D: original magnification X50, E: 
original magnification X100). F and G: nuclear and/or cytoplasmic staining for osterix   
was found in cells in the superficial lamina propria and within the surface epithelium (F: 
original magnification X50, G: original magnification X200).   
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Figure 14. Continued. 
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Figure 15.  Periostin and osterix expression in a case of fibroma from the buccal 
mucosa. A: This histology of the fibroma showed a thickened fibrous connective tissue 
in laminar propria and surface squamous epithelium with orthokeratin formation and a 
normal maturation pattern (H&E stain, original magnification X50) B: No periostin 
expression was found (original magnification X50). C: No osterix expression was found 
(original magnification X50). 
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Figure 16.  Periostin and osterix expression in a case of fibroma from the attached 
gingiva. A: This histology of the fibroma showed a thickened fibrous connective tissue 
in laminar propria and surface squamous epithelium with parakeratin formation and a 
normal maturation pattern (H&E stain, original magnification X50) B: Periostin 
expression was found in the superficial lamina propria and connective tissue (original 
magnification X50). C: Osterix expression was found in the surface epithelium and 
underlying connective tissue (original magnification X50). 
       
 
 
A B 
C 
